Indeed, a phase II trial testing combination nivolumab and ivosidenib treatment in patients with advanced IDH-mutant solid tumors is underway (NCT04056910), as well as a phase I trial testing combination pembrolizumab and vorasidenib treatment in patients with grades 2 and 3 IDH-mutant glioma (NCT05484622). This evidence concerns the gene IDH2 and glioma.